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Abstract
Cycles with progesterone elevation during controlled ovarian stimulation (COS) for IVF/ICSI
are commonly managed with a “freeze-all” strategy, due to a well-recognized detrimental
effect of high progesterone levels on endometrial receptivity. However, also a detrimental
effect of elevated progesterone on day-3 embryo quality has recently been found with
regards to top quality embryo formation rate. Because blastocyst culture and cryopreserva-
tion are largely adopted, we deemed relevant to determine whether this detrimental effect is
also seen on blastocyst quality on day 5–6. This issue was investigated through a large two-
center retrospective study including 986 GnRH antagonist IVF/ICSI cycles and using top
quality blastocyst formation rate as the main outcome. Results showed that on multivariate
analysis sperm motility (p<0.01) and progesterone levels at ovulation triggering (p = 0.01)
were the only two variables that significantly predicted top quality blastocyst formation rate
after adjusting for relevant factors including female age, BMI, basal AMH and total dose of
FSH used for COS. More specifically, progesterone levels at induction showed an inverse
relation with top quality blastocyst formation (correlation coefficient B = -1.08, 95% CI -1.9
to -0.02) and ROC curve analysis identified P level >1.49 ng/ml as the best cut-off for identifi-
cation of patients at risk for the absence of top quality blastocysts (AUC 0.55, p<0.01). Our
study is the first to investigate the top quality blastocyst formation rate in relation to proges-
terone levels in IVF/ICSI cycles, showing that increasing progesterone is associated with
lower rates of top quality blastocyst. Hence, the advantages of prolonging COS to maximize
the number of collected oocytes might eventually be hindered by a decrease in top quality
blastocysts available for transfer, if increasing progesterone levels are observed. This
observation extends the results of two recent studies focused on day-3 embryos and
deserves further research.
PLOS ONE | https://doi.org/10.1371/journal.pone.0176482 May 17, 2017 1 / 10
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Vanni VS, Somigliana E, Reschini M,
Pagliardini L, Marotta E, Faulisi S, et al. (2017) Top
quality blastocyst formation rates in relation to
progesterone levels on the day of oocyte
maturation in GnRH antagonist IVF/ICSI cycles.
PLoS ONE 12(5): e0176482. https://doi.org/
10.1371/journal.pone.0176482
Editor: Samuel Kim, University of Kansas Medical
Center, UNITED STATES
Received: January 9, 2017
Accepted: April 11, 2017
Published: May 17, 2017
Copyright: © 2017 Vanni et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and Supporting Information file.
Funding: The authors received no specific funding
for this work.
Competing interests: The authors of this
manuscript do not have any competing interests
existing inherent to the present study. As per
conflict of interests that are not inherent to the
present study, we report the following: VSV, MR,
SF, AP, EM, LP and WV have no competing
Introduction
Subtle progesterone elevation throughout Controlled Ovarian Stimulation (COS) for in vitro
fertilization (IVF) / intracytoplasmic sperm injection (ICSI) is a common occurrence that has
gained great attention over the last years, due to a well-documented detrimental impact on
endometrial receptivity [1]. In contrast, the majority of the available literature does not suggest
any harmful effects of elevated progesterone on oocyte maturation and competence [2–9]. As
a consequence, cycles with subtle progesterone elevation are commonly managed with a
freeze-all strategy, where the entire cohort of embryos/blastocysts is cryopreserved and a sub-
sequent frozen-thawed transfer is programmed [1,10–11]. However, quality assessment was
never the main outcome of recent studies conducted on elevated progesterone. Moreover, the
few previous studies focusing on embryo quality were conducted several years ago and most of
them included very small numbers of patients [2,12–14]. Thus, major biases and also a lack of
statistical power to detect a detrimental effect cannot be excluded. As a matter of fact, this
issue has recently become subject of some debate, as Huang et al. have described in a large
series of patients a decreased rate of top-quality embryo formation in relation to subtle proges-
terone elevation, regardless of the age of the woman, the basal FSH, the total dose of gonado-
tropins used or the duration of ovarian stimulation [15]. This is in accordance with another
recent study that found increasing serum P levels (1.60 ng/ml—2.50 ng/ml) to be associated
with decreased cumulative live birth rates [16]. Both studies focused on cleavage stage
embryos. Evidence on blastocyst quality is conversely very scanty. As blastocyst culture is now-
adays largely adopted and quality assessment remains a cornerstone in predicting the out-
comes of assisted reproduction [17–18], we deemed of interest determining whether a
negative effect of subtle progesterone elevation could be also observed on Day 5–6 of develop-
ment (blastocyst stage). This issue was investigated with the use of a large two-center retro-
spective study including 986 IVF/ICSI cycles.
Materials and methods
Study design
This was a retrospective, two-centres cohort analysis of patients treated at the infertility unit
Centro Scienze Natalità, San Raffaele Scientific Institute, Milan, Italy and at the infertility unit
Fondazione Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy between January 2013
and August 2016. Inclusion criteria were indication to IVF/ICSI, GnRH antagonist stimulation
protocol, cycle with blastocyst culture of the whole cohort of embryos formed and at least one
viable blastocyst on day 5–6 and availability of serum progesterone levels on the day of hCG
administration. To avoid the impact of intrinsic poor prognosis as a major bias related to blas-
tocyst development, the presence of a poor ovarian response (< 4 oocytes retrieved) [19] and/
or severe male factor [Total Motile Sperm Count (TMSC) < 5 million] [20] were both consid-
ered as exclusion criteria. All patient gave written informed consent for their anonymized
medical records to be used for clinical research purpose and the study was approved by the
Institutional Review Board of both participating centres (San Raffaele Scientific Institute,
Milan, Italy and Fondazione Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy).
Protocol for ovarian stimulation
All patients were treated with a GnRH antagonist protocol as previously described [21–22].
Briefly, both initial dose of FSH and dose adjustments during treatment were chosen on a
case-by-case basis according to patients’ characteristics. A daily dose of 0.25 mg of GnRH
antagonist was started on day 6 of stimulation. When three or more leading follicles had
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reached a diameter17 mm, triggering of ovulation was performed with 10,000 IU of high
purified (HP)-hCG or GnRH agonist 0.2 ml in case of risk of OHSS (presence of 25 follicles
with a diameter > = 12mm on the day of triggering). Oocyte collection was performed 36
hours after triggering of ovulation. Serum progesterone was systematically assessed on the day
of hCG administration in both centers.
Hormone measurements
At both centres, samples were tested for progesterone level in a Tosoh AIA fluorimetric system
with ST-AIA-PACK immunoassay (Tosoh Corporation) as previously described [6]. The assay
has a sensitivity of 0.1 ng/ml. Intra-assay and interassay variation coefficients were 11 and
13%, respectively. Besides the internal quality control checks performed daily by the institu-
tional laboratory, the assays were calibrated whenever a new reactive batch was used or when-
ever an outcome outside the normal range was observed. The assay was used for the entire
duration of the study and no corrective intervention had to be performed during the study
period.
Embryo culture and grading
After 2–3 hours incubation in Human Serum Albumin (HSA)-supplemented Fertilization
medium (Sage In-Vitro Fertilization, Inc. Trumbull, CT, USA) under oil, selected oocytes
were allocated to conventional in vitro fertilization or ICSI. For ICSI, denudation of the cumu-
lus oophorus was performed as previously described [23–24]. Inseminated or injected oocyte
were grouped cultured in microdrops of equilibrated HSA-supplemented Fertilization or
Serum Substitute Supplement (SSS, Irvine, CA, USA)-supplemented Cleavage medium (Sage
In-Vitro Fertilization, Inc. Trumbull, CT, USA) under oil respectively. Sixteen-eighteen hours
after insemination or ICSI, all oocytes were checked for fertilization as previously described
[23] and embryos were cultured until blastocyst stage in SSS (Irvine, CA, USA)-supplemented
Blastocyst medium (Sage In-Vitro Fertilization, Inc. Trumbull, CT, USA). As per inclusion cri-
teria, only patients who underwent blastocyst culture of the whole cohort of embryos formed
were included, hence no transfer or freezing of day-3 embryos was performed in the context of
this study. Blastocyst evaluation was performed according to the Istanbul Consensus [25].
Briefly, on the morning of day 5–6 of development, blastocysts were given a rating based on:
(i) the degree of expansion and hatching status (from 1 as early to 4 as hatched blastocyst); (ii)
the inner cell mass scored as follows: good- prominent, easily discernible, with many cells that
are compacted and tightly adhered together; fair- easily discernible, with many cells that are
loosely grouped together; poor—difficult to discern, with few cells; and (iii) the trophectoderm
scored as good -many cells forming a cohesive epithelium; fair—few cells forming a loose epi-
thelium and poor—very few cells. According to the Consensus, an optimal embryo at this
developmental stage is a fully expanded through to hatched blastocyst with a good inner cell
mass and a good trophectoderm. Based on this, ‘top quality’ blastocyst was defined as
expanded or hatched blastocyst with both an inner cell mass and multicellular trophectoderm
scored good or with only one of the two parameters scored fair and the other one scored good.
Blastocysts were never frozen before the expanded stage. In both centers, 95% of the embryo
assessment procedures were performed by the supervisors who were unaware of the study
hypothesis at the time of evaluation. Although the two units have no personnel in common,
they interact strictly for quality control procedures and scientific purposes [23]. In order to set
up embryologic studies from the two centers [23,26,27] a shared embryo quality control as
well as other subjective assessments (i.e. oocyte quality control, preimplantation diagnosis
biopsy control) is undertaken with a biannual frequency. Based on recent literature aimed at
Blastocyst quality and progesterone levels in IVF/ICSI cyles
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quantifying the subjective nature of blastocyst quality assessments [28], Cohen’s kappa score
[29] was calculated between the two embryologists evaluating blastocyst morphology and was
found to be 0.83 (95% CI: 0.60 to 1.00). This value revealed an “almost perfect” inter-observer
agreement between the embryologists [30].
Outcome measure
The main outcome of the study was the top quality blastocyst formation rate per fertilized
oocyte (2PN) cultured (%). Fertilization rate (number of 2PN per oocyte used) and blastulation
rate (number of blastocysts formed per 2PN cultured) were secondary outcomes.
Statistics
Data analysis was done with Statistical Package for Social Sciences (SPSS) version 23.0 (SPSS
Incl., USA). Univariate and multivariate linear regression analysis of factors related to the top
quality blastocyst formation rate were performed and the Beta (B) correlation coefficient and
95% Confidence Intervals (CI) of included variables were calculated. Receiver operating char-
acteristic (ROC) curve analysis was also performed and the optimal cut-off for negative out-
come prediction was calculated by maximizing Youden index (J). To avoid potential biases in
the results by assuming that any relationship between serum progesterone levels and top qual-
ity blastocyst formation rates may be linear, patients were also divided into distinct groups
according to the serum progesterone levels on the day of hCG administration (< or 1 ng/
ml,< or 1.5 ng ml,< or 2 ng ml, < or 2.5 ng ml) and non parametric tests (Kruskall-
Wallis test for independent samples) were used to compare top quality blastocysts formation
rates among the groups. All the tests were two-sided and a p value <0.05 was considered statis-
tically significant.
Results and discussion
A total of 1415 IVF/ICSI cycles were initially selected. N = 396 cycles were then excluded due
to presence of severe male factor infertility (TMSC < 5) and n = 33 cycles were excluded due
to poor ovarian response (< 4 oocytes retrieved), leaving n = 986 IVF/ICSI cycles for analysis.
Baseline characteristics and outcomes of the included cycles are shown in Table 1.
Univariate correlation analysis showed that female age (p = 0.04), sperm motility (p<0.01),
P at induction (p<0.01), technique used (ICSI vs IVF) (p<0.01) and fertilization rate
(p = 0.01) were significantly related to the top quality blastocyst formation rate (Table 2). All
relevant variables retrieved from univariate analysis together with duration of infertility -that
showed borderline significance (p = 0.05) on univariate analysis -were subsequently included
in the multivariate analysis of factors related to the top quality blastocyst formation rate.
Results of the multivariate analysis are also shown in Table 2: after controlling for all the rele-
vant confounders, only sperm motility (p<0.01) and P at induction (p = 0.01) remained signif-
icant predictors of top quality blastocyst formation rate.
To avoid potential biases in assuming a linear relationship between progesterone levels and
top quality blastocyst formation rates, patients were also divided in groups based on increasing
progesterone levels (< or 1 ng/ml, < or 1.5 ng ml, < or 2.0 ng ml and< or 2.5 ng
ml) and a significant reduction in top quality blastocyst formation rate in relation to increasing
P levels was confirmed with all the four cut-offs used (Fig 1). In contrast, P levels did not corre-
late significantly neither with fertilization rate (p = 0.17) nor with blastulation rate (p = 0.33)
(data not shown). ROC curve analysis for prediction of the absence of top quality blastocyst
(i.e. top quality blastocyst formation rate = 0%) based on P levels at induction showed a signifi-
cant Area Under the Curve (AUC) of 0.55 (p<0.01). By maximizing Youden index (J), we
Blastocyst quality and progesterone levels in IVF/ICSI cyles
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found that a P level>1.49 ng/ml is the best cut-off for identification of patients at risk for the
absence of top quality blastocyst (Fig 2).
This large retrospective study demonstrated that elevated serum progesterone on the day of
oocyte maturation induction is associated with decreased top quality blastocyst formation rate.
This observation is in line with a recent study that found decreased day-3 top quality embryo
formation rate in relation to subtle progesterone elevation in IVF cycles [15]. Compared to the
work by Huang and colleagues, we deemed relevant to include both IVF and ICSI cycles and
we found that the technique used for oocyte fertilization does not significantly influence the
detrimental effect of P levels at multivariate analysis. Similarly, we included both cycles where
HP-hCG or Gn-RH agonist was used for induction of ovulation, and univariate analysis failed
Table 1. Clinical features and IVF/ICSI cycle outcomes.
Clinical feature/outcome Median (IQR) or number (%)
Age (years) 35.7 (33.1–38.6)
BMI (Kg/m2) 21.2 (19.5–23.7)
Duration of infertility (years) 3.3 (2.2–5)
Basal FSH (IU/L) 6.7 (5.5–8)
Basal AMH (ng/mL) 2.6 (1.5–4.7)
Basal AFC 13 (9–19)
TMSC (Million) 49.3 (20.0–100.0)
Sperm volume (mL) 2.5 (2.0–3.5)
Sperm count (M/mL) 39.0 (17.7–55)
Sperm motility (%) 65.0 (50.0–90.0)
Cause of infertility
Idiopathic 253 (25.6)
Mild/moderate male factor 221 (22.4)
Reduced ovarian reserve 148 (15.0)
Tubal factor 135 (13.7)
Oligo-anovulation 134 (13.6)
Endometriosis 95 (9.6)
Technique used
IVF 330 (33.5)
ICSI 656 (66.5)
FSH starting dose (IU) 200 (150–225)
FSH total dose (IU) 1800 (1350–2400)
Duration of stimulation (days) 9 (8–10)
Induction of ovulation
10,000 HP-hCG (IU) 756 (76.4)
0,2 GnRH agonist (ml) 230 (23.3)
E2 at induction (pg/mL) 2260 (1574–3098)
P at induction (ng/mL) 0.9 (0.6–1.4)
Retrieved oocytes 10.5 (7–14)
Used oocytes 9 (6–11)
Fertilized oocytes 7 (5–9)
Fertilization rate (%) 80.0 (66.7–91.0)
Blastocysts 3 (2–4)
Blastulation rate (%) 44.4 (28.6–60.0)
Top quality blastocysts (n) 0.6 (0–1)
Top quality blastocysts formation rate (%) 8.5 (0–14.3)
https://doi.org/10.1371/journal.pone.0176482.t001
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to identify a significant effect of the triggering strategy on the top quality blastocyst formation
rate. Taken together, these data suggest that elevated progesterone levels at the end of COS are
detrimental to the in vitro developmental potential of the oocyte and that no triggering or fer-
tilization technique seems to ‘rescue’ the quality/competence of oocytes exposed to elevated
progesterone. There is in general limited data available on the impact of progesterone on
embryo quality, but as already discussed by Huang et al., [15], animal studies have documented
Table 2. Correlation analysis of factors related to the top quality blastocysts formation rate in IVF/ICSI cycles.
Variables Univariate analysis Multivariate analysis
B Correlation coefficient p value B Correlation coefficient (95% CI) p value
Female age -0.22 0.04 * -0.10 (-0.32 to 0.11) 0.36
BMI -0.04 0.71
Duration of infertility -0.03 0.05 (*) -0.02 (-0.05 to 0.00) 0.11
Basal AFC 0.11 0.06
Basal FSH 0.29 0.08
Basal AMH 0.05 0.70
Sperm count -0.01 0.50
Sperm motility 0.12 < 0.01* 0.11 (0.06 to 0.15) < 0.01*
FSH total dose -0.002 0.14
Induction of ovulation (HP-hCG vs GnRH agonist) -1.5 0.11
E2 at induction 0.09 x 10−3 0.74
P at induction -1.4 < 0.01* -1.08 (-1.9 to -0.02) 0.01*
Retrieved oocytes -0.002 0.98
Technique used (ICSI vs IVF) -3.41 < 0.01* -1.2 (-3.2 to 0.77) 0.23
Fertilization rate 0.06 0.01* 0.04 (-0.01 to 0.09) 0.16
https://doi.org/10.1371/journal.pone.0176482.t002
Fig 1. Relationship between serum progesterone levels and top-quality blastocyst formation rate.
With an increase in progesterone levels at induction, a decrease in top-quality blastocyst is observed. The
decrease in top-quality blastocyst formation rate was found to be statistically significant after dividing patients
into groups based on four different cut-off values of serum P levels: < or 1.0 ng/ml (p <0.01), < or
1.5 ng/ml (p <0.01), < or 2.0 ng/ml (p <0.01) and < or 2.5 ng/ml (p <0.01).
https://doi.org/10.1371/journal.pone.0176482.g001
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a progesterone-mediated regulation of oocyte competence [31–34]. Whether these differences
in blastocyst quality lead to decreased implantation and pregnancy rates in vivo deserves fur-
ther consideration. As a matter of fact, previous studies have shown that a frozen-thawed
embryo transfer can rescue cycles complicated by high P levels at induction, suggesting that
the main detrimental effect of P elevation is on endometrial receptivity within the fresh cycle.
However, published studies were mostly focused on pregnancy rates in the first frozen-thawed
embryo transfer rather than on cumulative pregnancy rates [1,35]. Hence, potential detrimen-
tal effects of P elevation on the quality of the whole cohort of blastocysts created has not been
thoroughly studied. A recent study that addressed cumulative live birth rates based on P levels
indeed found a significant detrimental effect of elevated P on cumulative outcomes, irrespec-
tive of poor, intermediate or high ovarian response [16]. Even if another small study recently
described similar cumulative live birth rates across groups of patients based on distribution of
P levels, results are difficult to interpret because power analysis was not calculated [11]. Inter-
estingly, a recent study has also described that P on the day of trigger is not related to euploidy
rates of the cohort of blastocyst created—however only a small number of patients was
included and further data on this subject would be of interest [36]. A previous study by our
group found similar blastulation rates between groups of patients undergoing a freeze-all strat-
egy with or without elevated progesterone, but was not powered to detect a difference in
Fig 2. ROC curve analysis for prediction of absence of top-quality blastocyst from progesterone
levels at induction. ROC curve analysis for prediction of the absence of top quality blastocyst based on P
levels at induction showed a significant AUC = 0.55 (p<0.01). The best cut-off for identification of
patients at risk for the absence of top quality blastocyst as obtained by maximization of Youden index is a P
level >1.49 ng/ml.
https://doi.org/10.1371/journal.pone.0176482.g002
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blastocyst quality [9]. In this larger study, we confirmed that blastulation rates are not
impaired by elevated progesterone but we found a significant decrease in top quality blastocyst
formation rate in relation to progesterone elevation. The fact that in this analysis we only
included GnRH antagonist and not GnRH agonist cycles to some extent also possibly contrib-
utes to the differences in the results observed with other recent studies [9,11,16,36]. Our obser-
vation may have relevant clinical implications. With the advent of the use of GnRH agonist
trigger and freeze all strategies, physicians have become more confident in the presence of a
hyper-response and, once decided for a freeze-all policy, they may be tempted to prolong the
duration of COS to maximize the number of collected oocytes. This delay may actually
increase the rate of subtle elevation of progesterone with hyperstimulation [37]. Based on our
results, the advantages of protacting COS might eventually be to some extent hindered by a
decrease in top quality blastocysts available for transfer, and a milder stimulation and/or an
earlier ovulation triggering might instead be indicated in high responders. More specifically,
based on ROC curve analysis in this study, P levels reaching or approximating 1.5 ng/ml could
be considered as a warning sign for decreased top quality blastocyst formation rate. In this
context, it should be noted that our results apply to GnRH antagonist cycles, that are the cur-
rently preferred protocol for maximizing oocyte yeald by prolonging COS and thus might
hold relevant clinical implications. However, to determine whether these differences in blasto-
cyst quality lead to decreased blastocyst competence in vivo further studies also encompassing
cumulative implantation and pregnancy outcomes are required.
Conclusions
Our study is the first to investigate the top quality blastocyst formation rate in relation to pro-
gesterone levels in IVF/ICSI GnRH antagonist cycles, showing that increasing progesterone is
associated with lower rates of top quality blastocyst. Our results thus extend the observation of
two recent studies focused on Day 3 embryos [15–16] and deserve further research.
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